Patient, donor, and transplantation characteristics
| No. of patients (%) | 60 (100%) | ||
| Sex, n (%) | |||
| Males | 32 (53%) | ||
| Females | 28 (47%) | ||
| Age at HSCT, y, median (range) | 7 (1-37) | ||
| Type of donor, n (%) | |||
| MFD | 20 (33%) | ||
| UD | 40 (67%) | ||
| Pesaro class at time of HSCT, n (%) | Whole cohort | MFD | UD |
| Class 1 | 27 (45%) | 12 (60%) | 15 (38%) |
| Class 2 | 17 (28%) | 4 (20%) | 13 (32%) |
| Class 3 | 4 (7%) | 1 (5%) | 3 (7%) |
| Adults | 12 (20%) | 3 (15%) | 9 (23%) |
| Human CMV serology, n (%) | |||
| Negative donor/negative recipient | 4 (7%) | ||
| Positive donor/negative recipient | 18 (30%) | ||
| Negative donor/positive recipient | 12 (20%) | ||
| Positive donor/positive recipient | 26 (43%) | ||
| Stem cell source, n (%) | |||
| BM | 47 (79%) | ||
| Umbilical cord blood | 11 (18%) | ||
| Peripheral blood stem cells | 2 (3%) | ||
| No. of cells infused | |||
| BM, × 108/kg, median (range) | 3.9 (0.5-13) | ||
| UCB, × 107/kg, median (range) | 4.2 (1.8-6) | ||
| CD34+ PBSCs, × 106/kg, median (range) | 4.8 and 6.5 | ||
| GVHD prophylaxis, n (%) | |||
| CsA* | 11 (18%) | ||
| CsA + MTX† | 9 (15%) | ||
| CsA + MTX + ATG‡ | 40 (67%) | ||
| No. of days to PMN recovery, median (range)§ | 20 (11-30) | ||
| No. of days to PLT recovery, median (range)¶ | 20 (11-36) | ||
| Graft failure, n (%)# | 5 (8%) | ||
| Chimerism at time of last follow-up, median (range)** | 100% (80-100) | ||
| No. of patients (%) | 60 (100%) | ||
| Sex, n (%) | |||
| Males | 32 (53%) | ||
| Females | 28 (47%) | ||
| Age at HSCT, y, median (range) | 7 (1-37) | ||
| Type of donor, n (%) | |||
| MFD | 20 (33%) | ||
| UD | 40 (67%) | ||
| Pesaro class at time of HSCT, n (%) | Whole cohort | MFD | UD |
| Class 1 | 27 (45%) | 12 (60%) | 15 (38%) |
| Class 2 | 17 (28%) | 4 (20%) | 13 (32%) |
| Class 3 | 4 (7%) | 1 (5%) | 3 (7%) |
| Adults | 12 (20%) | 3 (15%) | 9 (23%) |
| Human CMV serology, n (%) | |||
| Negative donor/negative recipient | 4 (7%) | ||
| Positive donor/negative recipient | 18 (30%) | ||
| Negative donor/positive recipient | 12 (20%) | ||
| Positive donor/positive recipient | 26 (43%) | ||
| Stem cell source, n (%) | |||
| BM | 47 (79%) | ||
| Umbilical cord blood | 11 (18%) | ||
| Peripheral blood stem cells | 2 (3%) | ||
| No. of cells infused | |||
| BM, × 108/kg, median (range) | 3.9 (0.5-13) | ||
| UCB, × 107/kg, median (range) | 4.2 (1.8-6) | ||
| CD34+ PBSCs, × 106/kg, median (range) | 4.8 and 6.5 | ||
| GVHD prophylaxis, n (%) | |||
| CsA* | 11 (18%) | ||
| CsA + MTX† | 9 (15%) | ||
| CsA + MTX + ATG‡ | 40 (67%) | ||
| No. of days to PMN recovery, median (range)§ | 20 (11-30) | ||
| No. of days to PLT recovery, median (range)¶ | 20 (11-36) | ||
| Graft failure, n (%)# | 5 (8%) | ||
| Chimerism at time of last follow-up, median (range)** | 100% (80-100) | ||
ATG indicates antithymocyte globulin; CsA, cyclosporine; MTX, Methotrexate; PMN, polymorphonuclear neutrophils; and PLT, platelets.
Recipients of HLA-identical sibling umbilical cord blood transplantation.
Recipients of HLA-identical sibling BM transplantation.
Recipients of UD HSCT.
Defined as the time needed to reach an absolute neutrophil count ≥ 0.5 × 109/L.
Defined as the time needed to reach an unsupported platelet count ≥ 20 × 109/L.
Defined as either the absence of hematopoietic reconstitution of donor origin on day +45 after the allograft (primary graft rejection) or as loss of donor cells after a transient engraftment of donor-origin hematopoiesis, with return to erythrocyte transfusion dependence (secondary graft rejection).
Hematopoietic chimerism was evaluated, starting from DNA obtained either from peripheral blood and/or BM mononuclear cells and cell subsets, by microsatellite analysis. Chimerism was analyzed at time of engraftment and at days +45, +60, +90, and +180. After these time points, chimerism analysis was performed at the time of each clinical control until 5 years after the allograft.